Deynet G, Reimer F
MMW Munch Med Wochenschr. 1979 Jun 15;121(24):831-2.
A placebo-controlled double-blind study of 30 patients with advanced chronic fatty liver was intended to show how far treatment with a liver preparation, in this case Hepavis, is superior to alcohol abstinence alone. Examination of the laboratory parameters, especially of gamma GT shows that treatment with Hepavis with simultaneous withdrawal of alcohol produces a rapid normalization or improvement of the laboratory findings and consequently an accelerated improvement in the course of the disease. This leads to the conclusion that the pathological activity of the liver cell is reduced more quickly by the constituents of Hepavis than without suitable therapy, and that a more favorable prognosis for the fatty liver as a potential precurser of cirrhosis is to be attained. Not only is elimination of the lipogenic factor, alcohol, essential in the treatment of fatty liver, but also treatment with hepatotropic substances.
一项针对30例晚期慢性脂肪肝患者的安慰剂对照双盲研究旨在表明，在这种情况下使用肝制剂（即肝维他）进行治疗比单纯戒酒优越到何种程度。对实验室参数的检查，尤其是γ-谷氨酰转肽酶的检查表明，使用肝维他并同时戒酒的治疗可使实验室检查结果迅速恢复正常或得到改善，从而加速疾病进程的改善。由此得出结论，与未进行适当治疗相比，肝维他的成分能更快降低肝细胞的病理活性，并且对于作为肝硬化潜在先兆的脂肪肝可获得更有利的预后。治疗脂肪肝不仅消除致脂因素酒精至关重要，使用亲肝物质进行治疗也同样重要。
